In vitro and in vivo experiments demonstrate how Salidroside inhibits ovarian cancer growth and promotes ferroptosis, suggesting new diagnostic avenues.
Emerging evidence suggests that ferroptosis resistance contributes to the ovarian cancer (OC) carcinogenesis. Here, the study identified a tumour promoting factor FSP1 and investigated the role of Salidroside in OC ferroptosis resistance. In vitro, Salidroside alleviated the ferroptosis resistance of OC cells, and promoted the ferroptosis features. In vivo, Salidroside could inhibit OC growth and stimulate the ferroptosis. Furthermore, Salidroside targeted the FSP1 to reduce FSP1 mRNA level, thereby assisted OC cells to ferroptosis. In public dataset, FSP1 expression was elevated in the OC single-cell transcriptome sequencing. In clinic, the FSP1 level was positively correlated to the O-RADS US grade. Taken together, these findings revealed an important role for Salidroside in OC ferroptosis resistance, which provided novel insight into ultrasonic diagnosis and traditional Chinese medicine in OC.
No takes yet. Share an insight, caveat, or question.
Hua et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: